Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Cornish, Katherine E ^a,b   De Villiers, Sabina H L ^a,b,c   Pravetoni, Marco ^a,b,d   Pentel, Paul R ^a,b,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' AMINOMETHYL NICOTINE RECOMBINANT PSEUDOMONAS EXOPROTEIN A CONJUGATE; 6' CARBOXYMETHYLUREIDO NICOTINE KEYHOLE LIMPET HEMOCYANIN CONJUGATE; ALUMINUM POTASSIUM SULFATE; ANTIBODY; FREUND ADJUVANT; NICOTINE SPECIFIC ANTIBODY; NICOTINE VACCINE; UNCLASSIFIED DRUG; HEMOCYANIN; IMMUNOLOGICAL ADJUVANT; KEYHOLE-LIMPET HEMOCYANIN; NICOTINE; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NONHUMAN; RAT; VACCINE PRODUCTION; ANIMAL; ANTIBODY PRODUCTION; IMMUNOLOGY; METABOLISM; SPRAGUE DAWLEY RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; HEMOCYANIN; MALE; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; VACCINES;

EID: 84891621851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082557     Document Type: Article

References (31)

1. Shen XY, Orson FM, Kosten TR (2012) Vaccines against drug abuse. Clin Pharmacol Ther 91: 60-70. PubMed: 22130115.
2. Raupach T, Hoogsteder PH, van Schayck CP (2012) Nicotine vaccines to assist with smoking cessation: Current status of research. Drugs 72: e1-e16. doi:10.2165/11633630-000000000-00000. PubMed: 22356293.
3. Moreno AY, Janda KD (2009) Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 92: 199-205. doi:10.1016/j.pbb.2009.01.015. PubMed: 19350728.
4. Pravetoni M, Le Naour M, Harmon TM, Tucker AM, Portoghese PS et al. (2012) An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther 341: 225-232. doi:10.1124/jpet.111.189506. PubMed: 22262924.
5. Anton B, Salazar A, Flores A, Matus M, Marin R et al. (2009) Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin 5: 214-229. doi:10.4161/hv.5.4.7556. PubMed: 19242094.
6. Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB et al. (2009) Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine 27: 7011-7020. doi:10.1016/j.vaccine.2009.09.072. PubMed: 19800446.
7. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB (2006) Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 34: 906-912. PubMed: 16507651.
8. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED et al. (2011) Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89: 392-399. PubMed: 21270788.
9. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD et al. (2009) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66: 1116-1123. doi: 10.1001/archgenpsychiatry.2009.128. PubMed: 19805702.
10. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K et al. (2008) A vaccine against nicotine for smoking cessation: A randomized controlled trial. PLOS ONE 3: e2547. PubMed: 18575629.
11. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J et al. (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78: 456-467. doi:10.1016/j.clpt.2005.08.007. PubMed: 16321612.
12. Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R (2004) Pneumococcal vaccines: an update on current strategies. Vaccine 22: 2209-2220. doi:10.1016/j.vaccine.2003.11.038. PubMed: 15149779.
13. Bryan JT (2007) Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 25: 3001-3006. doi:10.1016/j.vaccine.2007.01.013. PubMed: 17289220.
14. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR (2008) Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8: 1589-1594. doi:10.1016/j.intimp.2008.07.001. PubMed: 18656557.
15. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE et al. (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65: 191-198. doi:10.1016/S0091-3057(99)00206-3. PubMed: 10638653.
16. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR (2000) Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 22: 809-819. doi:10.1016/S0192-0561(00)00042-4. PubMed: 10963853.
17. Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP et al. (2012) Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 83: 543-550. doi: 10.1016/j.bcp.2011.11.004. PubMed: 22100986.
18. Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA et al. (1997) Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 283: 1076-1081. PubMed: 9399979.
19. Hieda Y, Keyler DE, VanDeVoort JT, Niedbala RS, Raphael DE et al. (1999) Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl) 143: 150-157. doi:10.1007/s002130050930. PubMed: 10326777.
20. Keyler DE, Shoeman D, LeSage MG, Calvin AD, Pentel PR (2003) Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J Pharmacol Exp Ther 305: 587-592. doi:10.1124/jpet.102.046805. PubMed: 12606612.
21. Keyler DE, Roiko SA, Benlhabib E, Lesage MG, St Peter JV et al. (2005) Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: Dose- and affinity-response relationships. Drug Metab Dispos 33: 1056-1061. doi:10.1124/dmd.105.004234. PubMed: 15843487.
22. LeSage MG, Shelley D, Pravetoni M, Pentel PR (2012) Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacol Biochem Behav 102: 157-162. doi:10.1016/j.pbb.2012.03.026. PubMed: 22503967.
23. Fahim RE, Kessler PD, Kalnik MW (2013) Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines 12: 333-342. doi:10.1586/erv.13.13. PubMed: 23496672.
24. Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC et al. (2013) Effect of a nicotine vaccine on nicotine binding to beta2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry 170: 399-407. doi:10.1176/appi.ajp.2012.12060793. PubMed: 23429725.
25. Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D et al. (2011) Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol 11: 1809-1815. doi:10.1016/j.intimp.2011.07.009. PubMed: 21802529.
26. Stills HF Jr. (2005) Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 46: 280-293. doi:10.1093/ilar.46.3.280. PubMed: 15953835.
27. Batista-Duharte A, Lindblad EB, Oviedo-Orta E (2011) Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett 203: 97-105. doi:10.1016/j.toxlet.2011.03.001. PubMed: 21392560.
28. Halperin SA, Langley JM, Eastwood BJ (1996) Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine. Clin Infect Dis 22: 59-62. doi:10.1093/clinids/22.1.59. PubMed: 8824967.
29. Pichichero ME, Passador S (1997) Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (hib) vaccine to infants and response to a booster dose of hib conjugate vaccine. Clin Infect Dis 25: 1378-1384. doi:10.1086/516154. PubMed: 9431382.
30. Vidor E (2007) The nature and consequences of intra- and inter-vaccine interference. J Comp Pathol 137: S62-S66. doi:10.1016/j.jcpa.2007.04.014. PubMed: 17560593.
31. Insel RA (1995) Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. In: JC WilliamsKL GoldenthalDL BurnsBP Lewis. Combined Vaccines and Simultaneous Administration: Current Issues and Perspectives. pp. 35-47.